News Category
In vitro ADME studies are critical for early assessment of drug candidates, improving success rates and reducing costs in pharmaceutical development.
GeoVax's next-generation MVA-X vaccine provides durable single-dose protection against lethal Clade I mpox and other orthopoxviruses, potentially simp...
Onco-Innovations is integrating manufacturing, preclinical, and regulatory efforts to advance its PNKP-targeting cancer therapy ONC010 toward first-in...
VERAXA Biotech has named Raju Willener as chief financial officer, bringing over 30 years of international capital markets experience as the company a...
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has retained IBN for corporate communications, aiming to raise awareness of its diverse portfol...
Regentis Biomaterials is advancing its GelrinC cartilage repair treatment with a U.S. pivotal trial and European commercialization efforts, targeting ...
Silo Pharma's U.S. patent allowance for SPC-15 strengthens its intellectual property portfolio and supports the development of a novel intranasal trea...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant that supports cartilage regeneration, with European approval and an FDA...
Med-X is expanding its Nature-Cide natural pest-control brand as it prepares for a Nasdaq listing, with recent OMRI certification opening opportunitie...
Telomir Pharmaceuticals announced that its lead drug candidate Telomir-Zn inhibited growth in human and canine osteosarcoma cell lines at similar low ...
Quantum BioPharma has received FDA clearance for its Investigational New Drug application for Lucid-MS, enabling a Phase 2 trial in multiple sclerosis...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the GEO-MVA Phase 3 trial could accelerate development of a new mpox vaccin...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNA gene therapy can restore full-length dystrophin and im...
Creative Biolabs has broadened its lipid-based delivery development capabilities to help researchers overcome stability, targeting, and controlled rel...
Creative Biolabs has expanded its single-cell multi-omics and RNA sequencing solutions, offering integrated services that enable high-resolution cellu...
A comprehensive review reveals that the tumor microenvironment actively reshapes natural killer cells into distinct functional subsets, offering new t...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its GEO-MVA vaccine and Gedeptin oncology programs, underscoring...
Regentis Biomaterials reports progress in its Phase III GelrinC trial, a 400% manufacturing yield increase, and a reduced net loss for the first half ...
Quantum BioPharma has received FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class drug that aims to protect and rebuild the myelin ...
TransCode Therapeutics has named John Tattory as interim CFO following Tom Fitzgerald's retirement, a leadership change that could affect the company'...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® T-cell engager and othe...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, is moving toward a Phase 2 trial in multiple sclerosis following FDA clear...
Quantum BioPharma receives FDA clearance to launch a Phase 2 trial of Lucid-MS, the first drug designed to shield and rebuild myelin in multiple scler...
Quantum BioPharma has received FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class drug that aims to shield and potentially rebuild ...
Helus Pharma's CEO will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, signaling the company's growing prominence ...
Onco-Innovations' CMO detailed the company's novel PNKP-targeting cancer drug ONC010, which uses synthetic lethality and nanoparticle delivery to pote...
American Fusion's Texatron fusion program has advanced to active testing with peak confinement pressures of 100,000 atmospheres, signaling progress to...
Quantum BioPharma's FDA clearance to proceed with a Phase 2 trial of Lucid-MS marks a significant step for a first-in-class multiple sclerosis therapy...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's progress in developing ENV-105 to overcome cancer drug r...
Nutriband's CEO will attend the Nasdaq LaB Biotech Summit, highlighting the company's focus on abuse-deterrent transdermal technology and its strategi...
Silo Pharma's participation in the IPAC-RS forum underscores the progress of its intranasal PTSD therapeutic, backed by robust stability data, signali...
Quantum BioPharma's Lucid-MS, a first-in-class candidate for multiple sclerosis, has cleared FDA Phase 2 trial approval, a significant step toward a p...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective drug candidate, has received FDA clearance to begin a Phase 2 trial, potentially tran...
Helus Pharma's CEO participation in a prominent investment conference underscores the company's advancing clinical pipeline for depression and anxiety...
GeoVax supports the new global mpox vaccine stockpile, highlighting its GEO-MVA candidate's readiness to contribute to sustainable and equitable vacci...
Voyageur Pharmaceuticals receives USD $1 million from Bayer after proving its iodine extraction process, advancing a potential domestic supply chain f...
Greenland Mines announced a Q4 2026 biotech spin-off, Nasdaq compliance, and a new acquisition with a high NPV, positioning it as a key rare earths pr...
VERAXA Biotech's appointment of Raju Willener as CFO brings extensive financial leadership to support its capital strategy and oncology pipeline devel...
Scinai Immunotherapeutics strategically pivots its R&D to its NanoAb platform and CDMO business after terminating its PC111 license with PinCell, aimi...
Onco-Innovations Ltd. strengthens its clinical foundation for its lead candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor, through manufactu...
OS Animal Health, a subsidiary of OS Therapies, presented its lead candidate OST-HER2 for canine osteosarcoma at the Disruptive Growth & Life Sciences...
Quantum BioPharma's FDA clearance to test Lucid-MS in a Phase 2 trial marks a pivotal step toward the first therapy that may repair myelin in MS patie...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a Phase 2 trial for MS marks a potential breakthrough in ...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the DRC, marking a critical step in developing an oral antivi...
Greenland Mines (NASDAQ: GRML) announced its Q4 2026 biotech spin-off and completed acquisition of the Sarfartoq project, positioning itself as a focu...
Quantum BioPharma gains FDA clearance to begin a Phase 2 trial of Lucid-MS in multiple sclerosis, a potential first-in-class therapy targeting demyeli...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class remyelination agent, marks a pivotal step toward a new approach fo...
Quantum BioPharma's FDA clearance for its Phase 2 trial of Lucid-MS marks a significant step toward a targeted treatment for multiple sclerosis, poten...
